A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure

Summary

This is a Phase II, multi-centre, randomized, double-blind, placebo-controlled, crossover study to evaluate the effect of AZD0780 Dose 1 versus placebo on systolic blood pressure (SBP) at Week 4, as measured by 24-hour ambulatory blood pressure monitoring (ABPM) in participants with ASCVD or risk equivalents and LDL-C ≥ 70 mg/dL, on stable medication.

Timeline

Start

2024-10-30

Primary completion

2025-04-18

Completion

2025-05-02

Drugs

Indications